UPADACITINIB (upadacitinib) by Aurobindo Pharma is janus kinase inhibitors [moa].
Drug data last refreshed 8h ago
Janus Kinase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Worked on UPADACITINIB at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.